Western blot data showed that +SA cells did not contain detectable levels of PPARγ when compared with MCF-7 and MDA-MB-231 human breast cancer cells suggesting that the antiproliferative effects of combined treatment of γ-tocotrienol with PPARγ antagonist may be mediated through PPARγ-independent mechanisms. This evidence concerns the gene PPARG and breast carcinoma.